Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
78 studies found for:    THPO
Show Display Options
Rank Status Study
1 Recruiting A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) With Different Frequencies in the Management of ITP
Condition: Immune Thrombocytopenia
Intervention: Drug: Recombinant Human Thrombopoietin (rhTPO)
2 Unknown  Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: recombinant human thrombopoietin (rhTPO); rituximab;   Drug: Dexamethasone
3 Unknown  Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: recombinant human thrombopoietin (rhTPO); dexamethasone;   Drug: Dexamethasone
4 Completed Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Conditions: Germ Cell Tumors;   Hepatic Cancer;   Neuroblastoma;   Osteosarcoma;   Rhabdomyosarcoma
Intervention: Drug: Recombinant Human Thrombopoietin
5 Recruiting A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: rituximab; recombinant human thrombopoietin (rhTPO);   Drug: Rituximab
6 Completed SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
Conditions: Thrombocytopenia;   Thrombocytopaenia
Interventions: Drug: SB497115;   Other: Placebo
7 Not yet recruiting Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Romiplostin
8 Unknown  Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Intervention: Drug: rhTPO in combination with Rituximab
9 Completed Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Condition: Cancer
Interventions: Biological: recombinant human thrombopoietin;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide;   Biological: G-CSF
10 Completed Thrombopoietin Levels and Platelet Transfusion in Neonates
Condition: Thrombocytopenia
Intervention:
11 Unknown  Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics
Condition: Immune Thrombocytopenia Response to Thrombopoietin Mimetics
Intervention:
12 Completed SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C
Conditions: Hepatitis C, Chronic;   Hepatitis C;   Thrombocytopenia
Interventions: Drug: SB497115;   Other: Placebo
13 Recruiting A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Interventions: Drug: Cyclosporin A;   Drug: rhTPO
14 Active, not recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Conditions: Anemia, Aplastic;   Anemia, Hypoplastic;   Thrombocytopenia
Interventions: Drug: Eltrombopag (Promacta);   Drug: Eltrombopag
15 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
16 Recruiting Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: recombinant human thrombopoietin
17 Recruiting Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy
Conditions: Immune Thrombocytopenia;   Pregnancy
Intervention: Drug: rhTPO
18 Recruiting Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
Conditions: Antineoplastic Adverse Reaction;   Thrombocytopenia;   Acute Myelocytic Leukemia
Intervention: Drug: rhTPO
19 Recruiting Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Condition: Idiopathic Thrombocytopenic Purpura
Intervention:
20 Recruiting Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT
Conditions: Allogeneic Hematopoietic Stem Cell Transplantation;   Myeloablative;   Delayed Platelet Engraftment
Intervention: Drug: Recombinant Human Thrombopoietin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years